Citations

Mayo Clinic

Showing 10 of 108522 citations.

The conundrum of underfeeding vs overfeeding neurocritically ill patients
Suárez, José I. , Vizzini, Angela, Freeman, William D. , Freeman, William D

Neurology | January 17, 2015 | Volume: 84 | Issue: 7 | Pages: 639-640

10.1212/wnl.0000000000001272 | PMID 25596502 Get It

Weight Loss, Saline Loading, and the Natriuretic Peptide System
Arora, Pankaj , Reingold, Jason, Baggish, Aaron L. , Guanaga, Derek, Wu, Connie , Ghorbani, Anahita , Song, Yanna, Chen‐Tournaux, Annabel, Khan, Abigail , Tainsh, Laurel T. , Buys, Emmanuel S. , Heublein, Denise M., Burnett, John C. , Semigran, Marc J., Bloch, Kenneth D., Scherrer‐Crosbie, Marielle , Newton‐Cheh, Christopher , Kaplan, Lee M. , Wang, Thomas J. , Williams, Jonathan S. , Arora, Pankaj , Baggish, Aaron L

Journal of the American Heart Association | January 17, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.1161/jaha.114.001265 | PMID 25595796 Get It

Background In epidemiologic studies, obesity has been associated with reduced natriuretic peptide ( NP ) concentrations. Reduced NP production could impair the ability of obese individuals to respond to salt loads, increasing the risk of hypertension and other disorders. We hypothesized that weight loss enhances NP production before and after salt loading. Methods and Results We enrolled 15 obese individuals (mean BMI 45±5.4 kg/m 2 ) undergoing gastric bypass surgery. Before and 6 months after surgery, subjects were admitted to the clinical research center and administered a large‐volume intravenous saline challenge. Echocardiography and serial blood sampling were performed. From the pre‐operative visit to 6 months after surgery, subjects had a mean BMI decrease of 27%. At the 6‐month visit, N‐terminal pro‐atrial NP (Nt‐pro ANP ) levels were 40% higher before, during, and after the saline infusion, compared with levels measured at the same time points during the pre‐operative visit ( P <0.001). The rise in Nt‐pro‐ ANP induced by the saline infusion (≈50%) was similar both before and after surgery (saline, P <0.001; interaction, P =0.2). Similar results were obtained for BNP and Nt‐pro BNP ; resting concentrations increased by 50% and 31%, respectively, after gastric bypass surgery. The increase in NP concentrations after surgery was accompanied by significant decreases in mean arterial pressure ( P =0.004) and heart rate ( P <0.001), and an increase in mitral annular diastolic velocity ( P =0.02). Conclusion In obese individuals, weight loss is associated with a substantial increase in the “setpoint” of circulating NP concentrations. Higher NP concentrations could contribute to an enhanced ability to handle salt loads after weight loss.
Clinical Implications of Intracoronary Imaging in Cardiac Allograft Vasculopathy
Matsuo, Yoshiki , Matsuzawa, Yasushi , Lerman, Lilach O. , Kushwaha, Sudhir S. , Guddeti, Raviteja R, Aoki, Tatsuo, Guddeti, Raviteja , Aoki, Tatsuo , Lerman, Amir

Circulation: Cardiovascular Imaging | January 17, 2015 | Volume: 8 | Issue: 1 | Pages: No page available

10.1161/circimaging.114.002636 | PMID 25596140 Get It

Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre‐transplant cytomegalovirus antibody titers predict outcome?
Bruminhent, Jackrapong , Dierkhising, Ross , Kremers, Walter K. , Theel, Elitza S. , Thongprayoon, Charat , Razonable, Raymund R. , Bruminhent, Jackrapong , Kremers, Walter K

Liver Transplantation | January 17, 2015 | Volume: 21 | Issue: 4 | Pages: 539-546

10.1002/lt.24078 | PMID 25597303 Get It

Despite preexisting cytomegalovirus (CMV) immunity, CMV‐seropositive liver transplantation (LT) patients remain at risk of CMV infection. We hypothesized that the pre‐transplant CMV antibody titer correlates with the risk of CMV reactivation. We conducted a retrospective study of CMV‐seropositive LT recipients who did not receive anti‐CMV prophylaxis from 2007 to 2013. The pre‐transplant CMV immunoglobulin G (IgG) titer, which was measured with an enzyme‐linked fluorescent immunoassay, was assessed as a risk factor for CMV reactivation with multivariate Cox proportional hazards models. The population consisted of 225 CMV‐seropositive LT patients with a median age of 57 years (interquartile range, 47‐62 years). The CMV titer distributions were as follows: <60 (40%) and ≥60 AU/mL (60%). The Kaplan‐Meier estimates for CMV infection were 17% at 3 months, 18% at 6 months, and 19% at 12 months after transplantation. In a univariate analysis, a marginally significant increased risk of CMV infection was seen in LT recipients with a pre‐transplant CMV IgG titer < 60 AU/mL versus ≥ 60 AU/mL [hazard ratio (HR), 1.79; 95% confidence interval (CI), 0.98‐3.28 (P =0.06)]. This risk was statistically significant in the subgroup of recipients who received allografts from CMV‐seropositive donors [HR, 2.21; 95% CI, 1.15‐4.26 (P =0.02)]. In a multivariate analysis, a pre‐transplant CMV IgG titer < 60 AU/mL was significantly associated with CMV infection [HR, 3.11; 95% CI, 1.60‐6.03 (P < 0.001)]. The other risk factors were high body mass index, donor CMV seropositivity, prolonged cold ischemic time, use of an interleukin‐2 receptor antagonist for induction therapy, and high numbers of post‐transplant infections. A lower pre‐transplant CMV antibody titer is significantly associated with CMV infection after LT. Quantitative measurement of CMV‐specific humoral immunity may have a potential role in improving the CMV prevention strategy in CMV‐seropositive LT recipients.Liver Transpl 21:539–546, 2015. © 2015 AASLD.
WWOX, large common fragile site genes, and cancer
Smith, David I, Gao, Ge , Smith, David I

Experimental Biology and Medicine | January 16, 2015 | Volume: 240 | Issue: 3 | Pages: 285-295

10.1177/1535370214565992 | PMID 25595185 Get It

WWOX is a gene that spans an extremely large chromosomal region. It is derived from within chromosomal band 16q23.2 which is a region with frequent deletions and other alterations in a variety of different cancers. This chromosomal band also contains the FRA16D common fragile site (CFS). CFSs are chromosomal regions found in all individuals which are highly unstable. WWOX has also been demonstrated to function as a tumor suppressor that is involved in the development of many cancers. Two other highly unstable CFSs, FRA3B (3p14.2) and FRA6E (6q26), also span extremely large genes, FHIT and PARK2, respectively, and these two genes are also found to be important tumor suppressors. There are a number of interesting similarities between these three large CFS genes. In spite of the fact that they are derived from some of the most unstable chromosomal regions in the genome, they are found to be highly evolutionarily conserved and the chromosomal region spanning the mouse homologs of both WWOX and FHIT are also CFSs in mice. Many of the other CFSs also span extremely large genes and many of these are very attractive tumor suppressor candidates. WWOX is therefore a member of a very interesting family of very large CFS genes.
Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States
Hirose, Ryutaro , Stock, Peter G. , Schladt, David P., Xiong, Hui , Liu, Jiannong , Olthoff, Kim M. , Harper, Ann, Kasiske, Bertram L. , Kim, W. Ray , Heimbach, Julie K. , Snyder, Jon J. , Israni, Ajay K.

Hepatology | January 16, 2015 | Volume: 61 | Issue: 5 | Pages: 1643-1650

10.1002/hep.27704 | PMID 25644186 Get It

The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non‐HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3‐month delay before granting a MELD exception score of 25, (2) a 6‐month delay before granting a score of 28, and (3) a 9‐month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n = 28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person‐years for the current policy and for 3‐, 6‐, and 9‐month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non‐HCC candidates. Conclusion: A delay of 6‐9 months would eliminate the geographic variability in the discrepancy between HCC and non‐HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates. (Hepatology 2015;61:1643–1650)
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial
Cavallin, M., Kamath, Patrick S. , Merli, Manuela , Fasolato, Silvano , Toniutto, Pierluigi , Salerno, Francesco , Romanelli, Roberto Giulio , Colletta, C. , Salinas, Freddy, Giacomo, Antonio Di , Ridola, Lorenzo , Fornasiere, Ezio, Caraceni, Paolo , Morando, Filippo, Piano, Salvatore , Gatta, Angelo, Angeli, Paolo , Bernardi, Mauro , Piano, Salvatore

Hepatology | January 16, 2015 | Volume: 62 | Issue: 2 | Pages: 567-574

10.1002/hep.27709 | PMID 25644760 Get It

Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment. Terlipressin with albumin is effective in the reversal of HRS. Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatment of HRS. The aim was to compare the effectiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of HRS in a randomized controlled trial. Twenty‐seven patients were randomized to receive terlipressin with albumin (TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group). The TERLI group received terlipressin by intravenous infusion, initially 3 mg/24 hours, progressively increased to 12 mg/24 hours if there was no response. The MID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice daily, with the dose increased to a maximum of 12.5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 μg thrice daily and up to 200 μg thrice daily. Both groups received albumin intravenously 1 g/kg of body weight on day 1 and 20‐40 g/day thereafter. There was a significantly higher rate of recovery of renal function in the TERLI group (19/27, 70.4%) compared to the MID/OCT group (6/21, 28.6%), P = 0.01. Improvement in renal function and lower baseline Model for End‐Stage Liver Disease score were associated with better survival. Conclusion : Terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal function in patients with HRS (H epatology 2015;62:567–574
Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndrome
Camilleri, Michael , Busciglio, Irene, Boldingh, Amy, Dyer, Roy B. , Zinsmeister, Alan R., Lueke, Alan J., Gray, Alan , Acosta, Andrés , Donato, Leslie J.

Alimentary Pharmacology & Therapeutics | January 16, 2015 | Volume: 41 | Issue: 5 | Pages: 438-448

10.1111/apt.13065 | PMID 25594801 Get It

Summary Background About one‐third of patients with IBS ‐diarrhoea (irritable bowel syndrome‐D) have evidence of increased bile acid synthesis or excretion. Aims To assess effects of the bile acid sequestrant, colesevelam, on faecal excretion of BA s, hepatic BA synthesis and diarrhoea in IBS ‐D; to appraise whether individual or random stool samples accurately reflect 48‐h total faecal bile acid excretion and proportions of the main bile acids excreted and to study the faecal fat excretion in response to colesevelam. Methods A single‐centre, unblinded, single‐dose trial of effects of colesevelam, 1875 mg [3 tablets (625 mg tablets)] orally, twice daily, for 10 days on total 48‐h faecal bile acid excretion and fasting serum C4 (7α‐hydroxy‐4‐cholesten‐3‐one; surrogate of hepatic bile acid synthesis). Stool diaries documented bowel functions for 8 days prior and 8 days during colesevelam treatment. Stool 48‐h samples and fasting serum were collected for faecal fat, faecal bile acid and serum C4. Results Colesevelam was associated with significantly increased faecal total bile acid excretion and deoxycholic acid excretion, increased serum C4 and more solid stool consistency. There was a significant inverse correlation between number of bowel movements per week and the total bile acid sequestered into stool during the last 48 h of treatment. Random stool samples did not accurately reflect 48‐h total or individual faecal bile acid excretion. Sequestration of bile acids by colesevelam did not increase faecal fat. Conclusions Colesevelam increases delivery of bile acids to stool while improving stool consistency, and increases hepatic bile acid synthesis, avoiding steatorrhoea in patients with IBS ‐D. Overall effects are consistent with luminal bile acid sequestration by colesevelam.
History of Hollenhorst Plaques
Graff‐Radford, Jonathan , Brown, Robert D. , Boes, Christopher J.

Stroke | January 16, 2015 | Volume: 46 | Issue: 4 | Pages: No page available

10.1161/strokeaha.114.007771 | PMID 25593136 Get It

Left Atrial Remodeling and Function in Advanced Heart Failure With Preserved or Reduced Ejection Fraction
Melenovský, Vojtěch , Hwang, Seok-Jae, Redfield, Margaret M. , Zakeri, Rosita , Lin, Grace , Borlaug, Barry A. , Hwang, Seok‐Jae , Borlaug, Barry A , Melenovský, Vojtěch , Zakeri, Rosita

Circulation: Heart Failure | January 15, 2015 | Volume: 8 | Issue: 2 | Pages: 295-303

10.1161/circheartfailure.114.001667 | PMID 25593126 Get It

Background— Left atrial (LA) structure and function are altered in most heart failure (HF) patients, but there may be fundamental differences in LA properties between HF with preserved (HFpEF) and reduced ejection fraction (HFrEF). Methods and Results— One hundred ninety-eight HF patients (51% HFpEF, New York Heart Association 3.1±0.7) and 40 HF-free controls underwent catheterization, echocardiography, and follow-up. Compared with controls, HF patients had larger and more dysfunctional left atria. At identical mean LA pressure (20 versus 20 mm Hg; P =0.9), HFrEF patients had larger LA volumes (LA volume index 50 versus 41 mL/m 2 ; P <0.001), whereas HFpEF patients had higher LA peak pressures, lower LA minimal pressures, higher LA stiffness (0.79 versus 0.48 mm Hg/mL; P <0.001), greater LA pulsatility (19 versus 13 mm Hg; P <0.001), and higher wall stress variations. Despite smaller LA volumes, better function, and less mitral regurgitation, HFpEF patients had more atrial fibrillation (42 versus 26%; P =0.02). LA dysfunction was associated with increased pulmonary vascular resistance and right ventricular dysfunction in both HF phenotypes. After a median follow-up of 350 days, 31 HFpEF and 28 HFrEF patients died. LA function (total LA EF) was associated with lower mortality in HFpEF (hazard ratio 0.43; 95% confidence interval, 0.2–0.9; P <0.05), but not in HFrEF. Conclusions— HFrEF is characterized by greater eccentric LA remodeling, whereas HFpEF by increased LA stiffness, which might contribute to greater atrial fibrillation burden. LA function is associated with pulmonary vascular disease and right HF in both HF phenotypes, but is associated with outcome more closely in HFpEF, supporting efforts to improve LA function in this cohort.